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Human mesangial cells and peripheral blood mononuclear cells
produce vascular permeability factor
KAZUMOTO IIJIMA, NORISHIGE YosHnwA, DANIEL T. CONNOLLY, and HAJIME NAKAMURA
Department of Pediatrics, Kobe University School of Medicine, Kobe, Japan, and Department of Health Sciences, Monsanto Company, St.
Louis, Missouri, USA
Human mesangial cells and peripheral blood mononuclear cells pro-
duce vascular permeability factor. Vascular permeability factor, or
vascular endothelial growth factor (VPF/VEGF) is a disulfide-linked
dimeric glycoprotein of about 40 kD that promotes fluid and protein
leakage from blood vessels. Various human tumor cell lines and cells
including fetal vascular smooth muscle cells produce VPF/VEGF.
Since glomerular mesangial cells (MC) are closely related to vascular
smooth muscle cells, we examined whether cultured human MC pro-
duce VPF/VEGF, Northern blotting analysis revealed that cultured
human MC expressed a 3.7 kilobases (kb) VPF/VEGF mRNA. Human
peripheral blood mononuclear cells (PBMC) also expressed VPF/VEGF
transcripts of 8.6 and 3.8 kb. Although the sizes of the transcripts
suggested the existence of unique molecular species of VPF/VEGF
mRNA in PBMC, RT-PCR analysis revealed that PBMC as well as
human MC expressed 121, 165, and 189 amino acid-containing isoforms
of VPF/VEGF, implying that there are no unique alternative splicing
products of VPFIVEGF mRNA in PBMC. Fetal calf serum and 12-o-
tetradecanoyl-phorbol-13-acetate (TPA) transiently enhanced VPF/VEGF
mRNA expression in cultured human MC. Transforming growth factor-al
enhanced VPF/VEGF mRNA expression in cultured human MC at least
within 24 hours. Dexamethasone (DEX) inhibited the TPA-induced
increase in VPF/VEGF mRNA expression, whereas DEX did not
change the basal level. That DEX depressed the TPA-induced increase
in VPF/VEGF mRNA expression is therefore probably a result of
transcriptional control. VPF/VEGF protein was detected in cultured
human MC with immunoperoxidase staining using anti-VPF/VEGF
antibody. TPA increased VPF/VEGF protein levels as well as those of
VPF/VEGF mRNA in cultured human MC. These findings indicate that
cultured human MC and PBMC produce VPF/VEGF and that it is
modulated by various agents. Since VPF/VEGF promotes growth in
vascular endothelial cells and enhances vascular permeability, VPF/
VEGF produced by MC and PBMC may induce the proliferation of
glomerular endothelial cells or enhance the permeability of glomerular
capillaries.
Vascular permeability factor (VPF), or vascular endothelial
growth factor (VEGF) is a dimenc heparin-binding glycoprotein
that was originally identified in guinea pig ascites and several
rodent tumor cell culture media [1—3]. Subsequently, VPFI
VEGF has been purified from the serum-free conditioned
medium of the human histiocytic lymphoma line U937 [4], other
cell lines and cells including human vascular smooth muscle
cells (VSMC) [5—10]. VPF/VEGF increases the fluid permeabil-
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ity in blood vessels when injected intradermally. VPFIVEGF
also has growth-promoting activity limited to vascular endothe-
hal cells in vitro and stimulates angiogenesis in vivo [2].
VPF/VEGF specifically binds to endothelial cells including
glomerular endothelial cells [11—13]. Recently, it has been
revealed that the fms-Iike tyrosine kinase is a receptor for
VPF/VEGF [14].
Since glomerular mesangial cells (MC) are closely related to
VSMC which produce VPF/VEGF [8], and since cell lines
derived from blood cells such as U937 [4, 151 and HL-60 [16]
produce VPF/VEGF, we examined whether cultured human
MC and human peripheral blood mononuclear cells (PBMC)
produce VPF/VEGF by Northern blotting, reverse transcrip-
tion-polymerase chain reaction (RT-PCR) and immunocyto-
chemistry. The data indicate that both cultured human MC and
human PBMC produce VPF/VEGF, and that VPF/VEGF ex-
pression by cultured human MC is increased by fetal calf serum
(FCS), l2-o-tetradecanoyl-phorbol-l3-acetate (TPA), as well as
transforming growth factor-f31 (TGF-f3l) and is depressed by
dexamethasone. Since VPF/VEGF promotes the growth of
vascular endothelial cells and enhances vascular permeability,
VPF/VEGF produced by MC and PBMC may induce the
proliferation of glomerular endothelial cells or enhance the
permeability of glomerular capillaries.
Methods
Materials
Collagenase, TPA and dexamethasone were purchased from
Sigma Chemical Company (St. Louis, Missouri, USA). TGF-/3l
was purchased from King Brewing Company (Kakogawa, Ja-
pan). Media 199 and HEPES were purchased from Gibco
(Grand Island, New York, USA). FCS was purchased from Cell
Culture Laboratories (Cleveland, Ohio, USA). Nu-serum was
purchased from Collaborative Research (Bedford, Massachu-
setts, USA). Lymphoprep'TM (lymphocyte separation medium)
was purchased from Nycomed Pharma As (Oslo, Norway).
Rabbit antibodies for the cytokeratins and factor VIII, normal
swine serum, biotinylated F(ab')2 fragment of swine anti-rabbit
immunoglobuhins, peroxidase-labeled streptavidin, 3, 3 diami-
nobenzidine tetrahydrochloride (DAB), hydrogen peroxide and
preimmune rabbit IgG were purchased from Dako Corporation
(Carpinteria, California, USA). Rabbit IgG against mouse im-
munoglobulins was purchased from Zymed Laboratories (San
Francisco, California, USA).
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Human glomerular mesangial cell culture
To establish human MC in culture, normal kidney portions
were separated from surgical specimens from patients undergo-
ing nephrectomy for kidney carcinomas. The renal capsule was
stripped and medullary tissue was removed. The cortex was
minced and passed through progressively finer sieves. The
resulting glomerular preparation was incubated with 0.1% col-
lagenase at 37°C for 20 minutes. The glomeruli were then
separated, washed and resuspended in media 199 containing
10% Nu-serum, 25 m HEPES, 2 mri L-glutamine, 100 UIml
penicillin and 100 mg/mi streptomycin. After 10 to 14 days,
cellular outgrowths were evident and by 21 days the cells had
attained confluence. About every 10 to 14 days, the confluent
cells were subcultured. The cells used in the present study
demonstrated characteristic stellate to fusiform morphology
and were resistant to the toxic effects of D-valine and puromy-
cm. Similar to VSMC in culture, they piled up, and in long-term
culture they formed "hillocks." They did not stain with anti-
bodies for the cytokeratins and factor VIII, indicating that they
are neither epithelial nor endothelial cells. Collectively, these
results are compatible with MC. Human MC derived from four
kidneys were used between passages 6 to 10.
Isolation of human PBMC
Human PBMC were separated from heparinized venous
blood by density-gradient centrifugation. Briefly, 20 to 25 ml of
heparinized venous blood was obtained from healthy volun-
teers. The blood was diluted in saline, overlaid onto Lym-
phoprepTM and centrifuged at 400 g for 40 minutes at 4°C. The
mononuclear cells at the interface were harvested and washed
in phosphate buffered saline three times. After washing, total
RNA was immediately isolated from the cells.
(32P] cDNA probe for human VPFIVEGF
A [32P} cDNA probe for human VPF/VEGF was prepared as
previously described [17]. Briefly, the 740 b polymerase chain
reaction (PCR) product encompassing the entire coding region
of the mRNA for the 189-amino acid form of human VPF plus
approximately 100 bp of 3' and 5' flanking sequences [15] was
cloned into the BamHI site of pUC18 (by Dr. Kim Sanzo,
Monsanto Co.). The NcoI-BamHI digest of this clone released
a 656 bp fragment which was the 740 bp fragment minus the
untranslated 5' flanking sequence and the adjacent nucleotides
encoding the amino terminal signal sequence for protein secre-
tion. This smaller fragment was labeled by oligolabeling
(Megaprime DNA labeling system, Amersham, UK) using
[a-32P] deoxycytidine triphosphate. This probe detected
mRNAs encoding the 206-, 189-, 165- and 121-amino acid forms
of human VPF/VEGF (VPF/VEGF2, VPF/VEGF189, VPF/
VEGF165, and VPF/VEGF12I).
RNA isolation and Northern blotting
Total RNA was isolated from the cells using guanidine
thiocyanate [18]. Total RNA (10 to 15 pjg) was size-fractionated
by electrophoresis on 1% agarose gel containing 3% formalde-
hyde and 0.5 g/ml of ethidium bromide, and transferred to
Hybond-N nylon membranes (Amersham) by capillary action in
10 x standard saline citrate (1 x SSC; 0.15 M NaCl and 0.015 M
sodium citrate). After baking at 80°C for three hours, the
membrane was prehybridized at 42°C overnight in 5 x SSC,
0.5% SDS, 3 x Denhardt's solution (1 X Denhardt's solution;
0.02% Ficoll, 0.02% polyvinylpyrolidone, and 0.02% BSA), 0.2
mglml salmon sperm DNA, and 45% formamide. The mem-
brane was hybridized in the same solution containing 1.0 x 106
cpm/ml of the 32P-labeled cDNA probe. After a 24-hour hybrid-
ization, the membrane was washed twice in 2 x SSC at room
temperature for five minutes, then twice in 2 x SSC containing
0.1% SDS at 65°C for 30 minutes. The membrane was exposed
to a Kodak X-Omat AR film with an intensifying screen at
—70°C. To quantify the relative amount of mRNA, the film was
scanned at 550 nm using a dual-wavelength TLC Scanner
(CS-930, Shimadzu, Kyoto, Japan) and the area corresponding
to each transcript was computed.
Reverse transcription and polymerase chain reaction
ampidication of VPFIVEGF mRNA
Oligonucleotide primers flanking the insertion/deletion site of
human VPF/VEGFI65 (codon 115) were synthesized [19]. The
sense primer was 5'-CGAAGTGGTGAAGTI'CATGGATG-3',
and the antisense primer was 5'-TTCTGTATCAGTCTT-
TCCTGGTGAG-3'.
Three micrograms of total RNA sediment were dissolved in 5
pl of RNase-free water containing 0.01 O.D. units of random
hexanucleotide primer (Takara, Kyoto, Japan) by heating at
65°C for 10 minutes then chilling on ice. Four microliters of
Moloney murine leukemia virus reverse transcriptase
(MMLVRT) buffer (GIBCO BRL, Gaithersburg, Maryland,
USA), 0.1 d of human placental ribonuclease inhibitor (110
U/pd, Takara), 1 tl of 5 mrvi DTT, 5 d of 5 m dNTPs, and 1
l of MMLVRT (200 U/ps, Takara) were added to each tube.
Reverse transcription was performed at 37°C for 60 minutes.
The reaction mixture was stored at —20°C.
Three microliters of reverse transcription products were
amplified by Taq DNA polymerase (Perkin Elmer Cetus, Nor-
walk, Connecticut, USA) in a 20 ,td reaction containing 10 mM
Tris-HC1 (pH 8.3), 50 mrvi KCI, 1.5 m MgCI2, 0.2 mrt dNTPs,
and 40 pmol of each primer. The reaction mix was overlaid with
20 sl of mineral oil. The PCR profile consisted of a seven-
minute initial denaturation at 94°C, followed by 40 cycles of one
minute of denaturation at 94°C, one minute of annealing at 60°C,
and three minutes of polymerization at 72°C, and finally a
seven-minute extension at 72°C.
Five microliters of the PCR reaction products were separated
by flat bed electrophoresis in 1% wt/vol agarose gels stained
with ethidium bromide and photographed.
Recombinant human VPFIVEGF
The 165 amino acid-containing isoform of recombinant hu-
man VPF/VEGF [16] was prepared from the serum-free condi-
tioned medium of baby hamster kidney (BHK) cells that had
been stably transfected with a cDNA for VPF/VEGF. High
level expression of VPF/VEGF was controlled by the herpes
virus immediate early promoter in conjunction with herpes
virus transactivator, VP-l6 (Paul Hippenmeyer and Maureen
Highkin, manuscript in preparation). The VPF/VEGF protein
was purified to homogeneity using cation exchange chromatog-
raphy and reversed-phase chromatography.
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Fig. 1. Vascular permeability factor (VPF/
VEGF) mRNA expression in cultured human
mesangial cells (MC) and human peripheral
blood mononuclear cells (PBMC). Total RNA
isolated from HL-60, a promyelocytic
leukemia cell line (15 sg), cultured human MC
(15 sg) and human PBMC (10 sg) was
electrophoresed and analyzed by Northern
blotting. The hybridized membranes were
exposed to Kodak X-Omat films for 5 days
and developed. A. HL-60 expressed a VPF/
VEGF transcript of 3.7 kilobases (kb). B.
Cultured human MC expressed a VPF/VEGF
transcript of 3.7 kb. C. Human PBMC
expressed VPF/VEGF transcripts of 8.6 and
3.8 kb; 28 S and 18 S denote the positions of
28 S and 18 S ribosomal RNA, respectively.
Anti- VPF/VEGF antibody
A rabbit polyclonal antibody was prepared at the Berkeley
Antibody Company (Richmond, California, USA) using VPF/
VEGF conjugated to keyhole limpet hemocyanin (KLH). The
conjugate was prepared by adding 25 d of a 10 mg/ml solution
of KLH (0.25 mg) to 48 tl of a 10 mglml solution of l-(3-
dimethylaminopropyl)-3-ethylcarbodiimide (EDC) in 20 ifiM
2-(N-morpholino) ethanesulfonate (MES) buffer, pH 4.5. This
was incubated for 20 minutes at room temperature on a shaker.
VPF/VEGF (2 mg) in 500 p.l of 20 mM MES buffer pH 7.5
containing 0.1% Tween 20 was added to the reaction tube, and
the mixture was incubated for two hours on a shaker at room
temperature. The conjugate was dialyzed overnight against
phosphate buffered saline at 4°C. Two rabbits received an initial
immunization with 200 tg of conjugate in Freund's complete
adjuvant followed by four booster injections containing 200 g
of conjugate in Freund's incomplete adjuvant. The permeabili-
ty-enhancing activity of VPF/VEGF was blocked in a Miles
assay at serum dilution of 1:100. IgG was purified using protein
A-sepharose chromatography.
Immunocytochemistry of VPFIVEGF
For immunoperoxidase staining, the human MC grown on
glass coverslips were rinsed, fixed in 3% paraformaldehyde for
10 minutes, and rinsed in Tris buffer. Fixed MC were incubated
with normal swine serum for five minutes to block non-specific
binding, then incubated with rabbit anti-human VPF/VEGF IgG
(5.2 g/ml diluted in 0.05 M Tris-HCI) for 30 minutes. After
rinsing, the cells were incubated with the biotinylated F(ab')2
fragment of swine anti-rabbit immunoglobulins for 30 minutes.
After rinsing, the cells were incubated in peroxidase-labeled
streptavidin diluted in Tris buffer for 10 minutes, then rinsed
again. The cells were subsequently incubated with substrate
(DAB and hydrogen peroxide) diluted in Tris buffer for 10
minutes, then rinsed with water. Preimmune rabbit IgG or
rabbit IgG against mouse immunoglobulins was used as a
negative control. After immunoperoxidase staining, the cells
were counter stained with Mayer's hematoxylin.
Statistical analysis
All values were expressed as mean standard error of the
mean. Statistical analysis was performed using Student's t-test.
Results
Expression of VPF/VEGF mRNA in cultured human MC and
PBMC
Since human VSMC produce VPF/VEGF and since MC are
closely related to VSMC, we examined whether MC represent
a potential source of VPF/VEGF. Total RNA was isolated from
cultured human MC and found by Northern analysis to contain
a VPF/VEGF transcript of 3.7 kilobases (kb) (Fig. 1B). The size
of transcripts was similar to that of HL-60, a promyelocytic
leukemia cell line (Fig. 1A). We also examined whether PBMC
express VPF/VEGF mRNA, since some cell lines derived from
blood cells produce VPF/VEGF [15, 16]. PBMC isolated from
healthy volunteers unequivocally expressed VPF/VEGF tran-
scripts of 8.6 and 3.8 kb (Fig. 1C).
The different sizes of the VPF/VEGF transcripts revealed by
Northern analysis prompted us to examine whether PBMC
express unique alternative splicing product(s) of VPF/VEGF
mRNA. We subjected VPF/VEGF mRNA to reverse transcrip-
tion-polymerase chain reaction (RT-PCR) using oligonucleotide
primers that detect all four molecular species of VPF/VEGF
[19]. HL-60 expressed bands of 403, 535, and 607 bp corre-
sponding to 121, 165, and 189 amino acid isoforms of VPF/
VEGF (VPF/VEGFI21, VPF/VEGFI65 and VPF/VEGF189), re-
spectively, which was consistent with the findings previously
reported [19]. PBMC as well as human MC expressed the above
three VPF/VEGF mRNA transcripts (Fig. 2), suggesting that
there are no unique alternative splicing products of VPF/VEGF
mRNA in PBMC.
We then addressed the effects of various agents on the levels
of VPF/VEGF transcripts in cultured human MC. After 48
hours of serum deprivation, 10% FCS induced a transient
increase in the amount of VPF/VEGF mRNA in cultured
human MC (O.D. ratio relative to GAPDH: untreated control;
0.066, FCS 2 hr; 0.151, FCS 6 hr; 0.105, FCS 24 hr; 0.069, mean
1051 —
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Fig. 2. Reverse transcription-polymerase chain reaction (RT-PCR) of
VPF/VEGF mRNA. RT-PCR products were separated in 1% agarose
gel and stained with ethidium bromide. Abbreviation M is molecular
marker (4'X 174 Hinc II digest). Lane 1, no template (negative control);
Lane 2, HL-60 (positive control); Lane 3, human MC; Lane 4, PBMC.
HL-60 expressed bands of 403, 535, and 607 bp corresponding 121, 165,
and 189 amino acid-containing isoforms of VPF/VEGF, respectively.
Both human MC and PBMC expressed the same three bands.
of 2 experiments; Fig. 3). After 48 hours of serum deprivation,
TPA (20 ng/ml) significantly increased the amount of VPF/
VEGF mRNA in the cultured human MC, reaching a maximum
at six hours (O.D. ratio relative to GAPDH: untreated control;
0.062 0.009, TPA 2 hr; 0.2 16 o.ois, P < 0.001, TPA 6 hr;
0.253 0.032, P = 0.001, N = 4), and returning to the untreated
level at 24 hours (O.D. ratio relative to GAPDH: 0.071 0.006,N = 4; Fig. 4). TGF-/31 (2 nglml) induced an increase in
VPF/VEGF mRNA expression at least within 24 hours (O.D.
ratio relative to GAPDH: untreated control; 0.065 0.009,
TGF-f31 6 hr; 0.142 0.08, p <0.005, TGF-/31 24 hr; 0.145
0.022, P < 0.05, N = 3; Fig. 5). After 48 hours of serum
deprivation, 4 sg/ml dexamethasone (DEX) significantly inhib-
ited the TPA-induced increase in VPF/VEGF mRNA expres-
sion (O.D. ratio relative to GAPDH: TPA 6 hr; 0.288 0.03 1,
TPA + DEX 6 hr; 0.144 0.026, p < 0.05, N 4), although
TPA + DEX for six hours still induced a significant increase in
VPF/VEGF mRNA expression compared with the untreated
control (O.D. ratio relative to GAPDH: untreated control; 0.048
0.010, TPA + DEX 6 hr; 0.144 0,026, P < 0.05, N = 4).
Dexamethasone did not depress the basal level of VPF/VEGF
mRNA expression (O.D. ratio relative to GAPDH: 0.057
0.004, N = 3; Fig. 6).
Detection of VPF/VEGF protein by immunocytochemistry
To confirm that MC produce VPF/VEGF protein as well as
mRNA, a specific rabbit anti-VPF/VEGF IgG was used for
immunocytochemical staining. When cultured human MC were
incubated with 20 ng/ml TPA for six hours after serum depri-
vation for 48 hours, no signal was detected using preimmune
rabbit IgG (not shown) or rabbit IgG against anti-mouse immu-
noglobulins (Fig. 7A), whereas VPF/VEGF protein was de-
tected in virtually all of the MC incubated with TPA for six
Fig. 3. Effects of fetal calf serum (FCS) on the level of VPF/VEGF
mRNA in cultured human MC. After 48 hours of serum deprivation
(0.5% FCS), the culture medium was exchanged with 10% FCS con-
taining medium at the indicated periods prior to total RNA isolation.
Total RNA (15 sg) was electrophoresed and analyzed by Northern
blotting. The exposure time was 72 and 6 hours for VPF/VEGF and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively.
A. A typical Northern blot. FCS transiently increased VPF/VEGF
mRNA, whereas expression of a housekeeping gene, GAPDH mRNA
was not changed. B. The VPF/VEGF mRNA/GAPDH mRNA ratios are
shown. Values represent the mean of 2 experiments.
hours (Fig. 7B). Preincubation of 125 g/ml recombinant human
VPF/VEGF with anti-VPF/VEGF antibody (5.2 /.LgIml) (more
than 20-fold excess of antigen) blocked the VPF/VEGF signal in
MC exposed to TPA for six hours (Fig. 7C), indicating that the
anti-VPF/VEGF antibody was specific for human VPF/VEGF.
Control MC (Fig. 7D) as well as those exposed to TPA for 24
hours (Fig. 7E) were less intensely stained than those exposed
to TPA for six hours. The time course of immunostaining of
TPA-treated cells was consistent with the results in Northern
blotting.
Discussion
We demonstrated that both cultured human MC and PBMC
expressed VPF/VEGF mRNA. Cultured human MC expressed
a VPF/VEGF transcript of 3.7 kb, whereas human PBMC
expressed VPF/VEGF transcripts of 8.6 and 3.8 kb. Tischer et
al have reported that human VSMC contain 5.5, 4.4 and 3.7 kb
transcripts [8]. Others have reported that U937 cells contain a
3.8 kb transcript [13] or at least eight different transcripts
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Fig. 4. Effects of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) on the
level of VPFIVEGF mRNA in cultured human MC. After 48 hours of
serum deprivation (0.5% FCS), 20 ng/ml TPA was added to culture
medium at the indicated periods prior to isolation of total RNA. Total
RNA (15 rg) was electrophoresed and analyzed by Northern blotting.
A. A typical Northern blot. TPA increased VPF/VEGF mRNA reaching
a maximum at 6 hours, whereas GAPDH mRNA was not changed. B.
VPF/VEGF mRNAIGAPDH mRNA ratios were significantly increased
after 2 and 6 hours of exposure, and returned to the basal level within
24 hours (N = 4). * P < 0.005 vs. untreated control.
between 9.5 and 1.4 kb [17], and that bovine pituitary folliculo-
stellate cells contain only a 3.7 [16] or 4.2, 3.7 and 3.4 kb
transcripts [20]. Thus, the pattern of VPF/VEGF mRNA ex-
pression is extremely variable.
Alternative splicing of VPF/VEGF mRNA can produce four
isoforms of VPF/VEGF. These four isoforms encode identical
amino-terminal residues, including a 26-amino acid hydropho-
bic signal sequence. With cleavage of this signal peptide,
proteins of 121, 165, 189, and 206 amino acids (VPF/VEGFI2I,
VPF/VEGFI6S, VPF/VEGF189, VPF/VEGF2, respectively)
are generated. The deletion in VPF/VEGF121 begins at codon
116 of the mature form of VPF/VEGFI65 and involves a
contiguous stretch of 44 amino acids before terminating in the
identical five carboxy-terminal residues. Both VPF/VEGF189
and VPF/VEGF2Ø contain the entire sequence of VPF/
VEGFI6S as well as an additional 24 amino acids inserted at the
same site that begins the deletion in VPF/VEGF12I. An addi-
tional 17 amino acids due to alternative choices of a 5'-splice
donor site may also be encoded generating VPFIVEGF2Ø6.
The difference in the size of VPF/VEGF transcripts in
Northern analysis prompted us to examine whether PBMC
Fig. 5. Effects of transforming growth factor-f31 (TGF-131) on the level
of VPF/VEGF mRNA in cultured human MC. After 48 hours of serum
deprivation (0.5% FCS), TGF-/3l (2 nglml) was added to the culture
medium at the indicated periods prior to isolatior of total RNA. Total
RNA (15 g) was electrophoresed and analyzed by Northern blotting.
A. TGF-J3l increased VPFIVEGF mRNA expression within 24 hours,
whereas the level of GAPDH mRNA was not changed. B. VPF/VEGF
mRNA/GAPDH mRNA ratios were significantly increased after expo-
sure for 6 and 24 hours. * P < 0.005 and ** P < 0.05 vs. untreated
control.
express unique alternative splicing product(s) of VPF/VEGF
mRNA. We therefore subjected VPFIVEGF mRNA to RT-PCR
using oligonucleotide primers flanking the insrtion/de1etion site
of VPF/VEGF 165• These primers can detect mRNA encoding all
four molecular species of VPF/VEGF [19]. We found that
PBMC as well as human MC expressed VPF/VEGF12I, VPF/
VEGFI6S and VPFIVEGFI89, suggesting that there are no
unique alternative splicing products of VPF/VEGF mRNA in
PBMC. The large size transcript in PBMC, therefore, may be
nonspecific binding of VPF/VEGF cDNA probe, or a transcript
derived from homologs, but not alternative splicing products of
VPF/VEGF.
Tischer et al have reported that TPA increases VPF/VEGF
mRNA expression in cultured human VSMC [8]. Dolecki and
Connolly have also reported that TPA and TGF-/3l enhance
VPF/VEGF mRNA expression in the histiocytic lymphoma cell
line, U937 [17]. We found that VPF/VEGF mRNA expression
in cultured human MC was enhanced by FCS, TPA and
TGF-pl, which was consistent with the findings previously
reported. Moreover, the immunocytochemical study revealed
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Fig. 6. Effects of dexamethasone (DEX) on the level of VPF/VEGF
mRNA in cultured human MC. After 48 hours of serum deprivation,
DEX (4 g/ml), TPA (20 ng/mI), or TPA (20 ng/ml) + DEX (4 g/ml)
was added to the culture media at 6 hours prior to total RNA isolation.
Total RNA (15 pig) was electrophoresed and analyzed by Northern
blotting. A. DEX decreased the TPA-induced increase in VPFIVEGF
mRNA expression, whereas the basal VPF/VEGF mRNA expression
was not changed. B. VPF/VEGF mRNAJGAPDH mRNA ratios are
shown, DEX reduced the level of TPA-induced increase in VPF/VEGF
mRNA expression, although TPA + DEX still induced a significant
increase in VPF/VEGF mRNA expression. * P < 0.001 vs. untreated
control, ** P < 0.05 vs. TPA and vs. untreated control.
that TPA transiently induced the production of VPF/VEGF
protein as well as mRNA. Since long-term exposure to TPA
depletes protein kinase C, the return of VPF/VEGF mRNA
expression to the untreated level after 24 hours in TPA is
probably due to the depletion of protein kinase C. Indeed, the
TPA effect on VPF/VEGF mRNA expression was blunted after
the depletion of protein kinase C with the long-term TPA
treatment (O.D. ratio relative to GAPDH: untreated + TPA 6
hr; 0.249, TPA 36 hr pretreated + TPA 6 hr; 0.132, the mean of
2 experiments).
Recently, Berse et al have reported that VPF/VEGF tran-
scripts were detected in guinea pig and human kidneys by
Northern blotting. VPF/VEGF transcripts were detected by in
situ hybridization at the periphery of glomerular loops, a
location suggestive of glomerular epithelial cells in adult guinea
pigs [21]. The same group revealed VPF/VEGF mRNA and
protein expression in normal adult human glomerular epithelial
cells [22]. Thus, it is possible that VPF/VEGF is mainly
produced by glomerular epithelial cells in normal glomeruli.
The present data indicate that glomerular MC are also a
potential source of VPF/VEGF. This may be physiologically
Fig. 7. Immunocytochemistry of VPF/VEGF in cultured human MC.
Cultured human MC grown on glass coverslips were deprived of serum
(0.5% FCS) for 48 hours, then stimulated with 20 ng/ml TPA and
analyzed by the immunoperoxidase staining using anti-VPF/VEGF IgG.
A. Rabbit IgG against mouse immunoglobulins was the primary anti-
body (negative control). B. VPF/VEGF protein was detected in MC
exposed to TPA for 6 hours. C. Pre-incubation with over a 20-fold
excess of recombinant human VPF/VEGF with rabbit antibody for
VPF/VEGF resulted in a loss of the signal in MC exposed to TPA for 6
hours. D. Untreated MC produced faint levels of VPF/VEGF, E.
Twenty-four hours after TPA exposure, VPFIVEGF protein in MC was
decreased compared with that in the MC exposed to TPA for 6 hours (B).
significant since glomerular MC are in direct contact with the
target of VPF/VEGF, glomerular endothelial cells. Thus, if MC
produce VPF/VEGF in vivo, it could quite effectively regulate
glomerular endothelial cell function.
TGF-/31 and, the protein kinase C activating cytokine, plate-
let-derived growth factor are believed to be involved in an
experimental mesangial proliferative glomerulonephritis [23—
25]. Since TGF-/31 was shown here to induce VPF/VEGF in
MC, under the above pathological conditions, it is possible that
VPF/VEGF production by MC increases and that the biological
activity of VPFIVEGF is induced, although this remains to be
elucidated.
It is of interest that the synthetic glucocorticoid, dexameth-
asone, significantly depressed the TPA-induced increase in
VPF/VEGF mRNA expression. Jonet et al, Yang-Yen et al, and
SchUle et al have reported that glucocorticoid inhibits TPA-
induced transcription of collagenase gene by interfering with
AP-l, the major enhancer factor of the collagenase promoter
[26—28]. The promoter region of VPF/VEGF gene in cultured
human VSMC also contains AP-l sites [81. Thus, the dexa-
methasone-induced depression of TPA-induced VPF/VEGF
mRNA expression may be due to a transcriptional control
mechanism similar to that in the collagenase gene. Alterna-
tively, the promoter region of the VPF/VEGF gene might
possess a negative glucocorticoid responsive element(s) which
a
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has not been identified in VPF/VEGF gene so far. Dexameth-
asone may change the stability of VPF/VEGF mRNA. How-
ever, the basal VPF/VEGF mRNA level was not depressed by
dexamethasone. Thus, it is unlikely that the dexamethasone-
induced depression of TPA-induced VPF/VEGF mRNA ex-
pression is due to the reduced stability of VPF/VEGF mRNA,
although definite proof awaits a reporter gene expression assay
such as the CAT assay. Since TPA + dexamethasone still
induced a significant increase in VPF/VEGF mRNA expres-
sion, the TPA effect on VPF/VEGF mRNA expression may be,
at least in part, due to a transcriptional factor(s) other than
AP- 1.
Since VPF/VEGF is an extremely potent agent in promoting
fluid and protein extravasation in guinea pig skin [1, 4], it may
also promote protein leakage from glomerular capillaries, in-
ducing proteinuria. Experiments are currently in progress to
investigate the effects of VPF/VEGF infusion on urinary albu-
min excretion and glomerular filtration rate. VPF/VEGF pro-
motes the growth of vascular endothelial cells and enhances
vascular permeability [2, 4, 6, 29]. It is therefore possible that
VPF/VEGF produced by MC and/or PBMC plays a role in the
maintenance and repair of the glomerular endothelium.
In summary, this study revealed that cultured human MC and
PBMC produce VPF/VEGF and that VPF/VEGF production is
enhanced by FCS, TPA and TGF-pl and depressed by dexa-
methasone, possibly at the transcriptional level. These findings
suggest that VPF/VEGF produced by MC and/or PBMC in-
duces the proliferation of glomerular endothelial cells or en-
hances the permeability of glomerular capillaries. Further stud-
ies are required to elucidate the role of VPF/VEGF in human
glomerular diseases and in experimental models.
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